Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Rivoglitazone HCl
rivoglitazone HCl
rivoglitazone HCl
pioglitazone HCl
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring rivoglitazone HCl, pioglitazone HCl, thiazolidinedione, peroxisome proliferator-activated receptor gamma (PPAR gamma), type 2 diabetes mellitus
Eligibility Criteria
Inclusion Criteria:
- type 2 diabetes
- HbA1c >6.5% and <10.0%
- FPG >126 mg/dL (7 mmol/L) and < 270 mg/dL (15 mmol/L)
Exclusion Criteria:
- History of type 1 diabetes
- History of ketoacidosis
- Current insulin therapy
- C-peptide <0.5ng/mL
- Imparied hepatic function
- NYHA Class II-IV cardiac status or hospitalization for CHF or EF<40%
- uncontrolled hypertension
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
Arm Label
1
2
3
4
5
Arm Description
0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
30 mg pioglitazone HCl capsules once daily for 12 weeks
Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
Outcomes
Primary Outcome Measures
Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo
Secondary Outcome Measures
Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl
Full Information
NCT ID
NCT00575874
First Posted
December 14, 2007
Last Updated
February 6, 2009
Sponsor
Daiichi Sankyo Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT00575874
Brief Title
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
Acronym
RAISE
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Dose and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
January 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Daiichi Sankyo Co., Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
rivoglitazone HCl, pioglitazone HCl, thiazolidinedione, peroxisome proliferator-activated receptor gamma (PPAR gamma), type 2 diabetes mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Arm Title
2
Arm Type
Experimental
Arm Description
1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Arm Title
3
Arm Type
Experimental
Arm Description
1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Arm Title
4
Arm Type
Active Comparator
Arm Description
30 mg pioglitazone HCl capsules once daily for 12 weeks
Arm Title
5
Arm Type
Placebo Comparator
Arm Description
Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
Intervention Type
Drug
Intervention Name(s)
Rivoglitazone HCl
Intervention Description
0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
rivoglitazone HCl
Intervention Description
1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
rivoglitazone HCl
Intervention Description
1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
pioglitazone HCl
Intervention Description
30 mg capsules once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
matching tablets or capsule once daily for 12 weeks
Primary Outcome Measure Information:
Title
Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
type 2 diabetes
HbA1c >6.5% and <10.0%
FPG >126 mg/dL (7 mmol/L) and < 270 mg/dL (15 mmol/L)
Exclusion Criteria:
History of type 1 diabetes
History of ketoacidosis
Current insulin therapy
C-peptide <0.5ng/mL
Imparied hepatic function
NYHA Class II-IV cardiac status or hospitalization for CHF or EF<40%
uncontrolled hypertension
Facility Information:
City
Hong Kong
Country
China
12. IPD Sharing Statement
Learn more about this trial
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
We'll reach out to this number within 24 hrs